Regeneron Gets Novartis Syringe Patent Axed At PTAB
The Patent Trial and Appeal Board has found that more than two dozen claims in a Novartis pre-filled eye injection syringe patent weren't patentable, handing Regeneron a win in a larger...To view the full article, register now.
Already a subscriber? Click here to view full article